Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 857-860

  Cornejo, Agustin ^a   Bohnenblust, Mary ^a   Harris, Catherine ^a   Abrahamian, Gregory A ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Complication; Intestinal perforation; Liver transplantation; Post transplantation lymphoproliferative disorder; Rituximab

Indexed keywords

RITUXIMAB; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; B CELL LYMPHOMA; CASE REPORT; DEATH; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL LYMPH NODE; INTESTINE ANASTOMOSIS; INTESTINE NECROSIS; INTESTINE PERFORATION; JEJUNUM TUMOR; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE ORGAN FAILURE; PERITONITIS; PNEUMATOSIS INTESTINALIS; PNEUMOPERITONEUM; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RECURRENT INFECTION; SINGLE DRUG DOSE; SMALL INTESTINE RESECTION; UMBILICAL HERNIA;

ANTIBODIES, MONOCLONAL; HEPATITIS C, CHRONIC; HUMANS; INTESTINAL PERFORATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED;

EID: 68149137742     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1062-1     Document Type: Article

References (10)

1. WK Kremers HC Devarbhavi RH Wiesner RA Krom WR Macon TM Habermann 2006 Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival Am J Transplant 6 5 Pt 1 1017 1024
2. J Svoboda R Kotloff DE Tsai 2006 Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab Transpl Int 19 4 259 269
3. Hsu YC, Liao WC, Wang HP, Yao M, Lin JT (2007) Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder. Dig Liver Dis 13 December [Epub ahead of print]
4. O Kollmar S Becker MK Schilling CA Maurer 2002 Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy Transplantation 73 4 669 670
5. (No authors listed) (2002) Rituximab: first report of intestinal perforations in an elderly patient: case report. Reactions. 2002:1(901):14-15(2)
6. (No authors listed) (2007) Rituximab: gastrointestinal perforation. Prescrire Int October;16(91):201
7. Health Canada, reports of bowel obstruction and gastrointestinal perforations with Rituxan. Rituximab. 10 November 2006. Website: http://www.hc-gc.gs.ca. Accessed October 2006, 3 p
8. JJ Ifthikharuddin LA Mieles JD Rosenblatt CK Ryan DM Sahasrabudhe 2000 CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab Am J Hematol 65 2 171 173
9. V Leblond N Dhedin MF Mamzer Brunel S Choquet O Hermine R Porcher 2001 Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders J Clin Oncol 19 772 778
10. MB Tang ES Tan SH Tan 2008 Late onset Epstein Barr virus negative post-transplant lymphoproliferative disorder presenting as ulcerated necrotic papules and nodules in a renal transplant patient Australas J Dermatol 49 2 100 102